ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by EAM Investors LLC

EAM Investors LLC reduced its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 13.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 235,813 shares of the biotechnology company's stock after selling 36,821 shares during the period. EAM Investors LLC owned 0.10% of ADMA Biologics worth $4,044,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock worth $312,109,000 after buying an additional 80,302 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of ADMA Biologics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock valued at $93,187,000 after acquiring an additional 50,399 shares during the last quarter. Renaissance Technologies LLC grew its position in ADMA Biologics by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company's stock worth $64,654,000 after purchasing an additional 102,692 shares during the period. Perpetual Ltd purchased a new position in ADMA Biologics during the fourth quarter valued at approximately $62,300,000. Finally, Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics during the third quarter worth $61,858,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 1.2 %

ADMA Biologics stock traded down $0.25 during midday trading on Monday, reaching $21.06. The company's stock had a trading volume of 875,623 shares, compared to its average volume of 3,606,749. ADMA Biologics, Inc. has a fifty-two week low of $6.19 and a fifty-two week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business has a 50-day simple moving average of $18.26 and a 200-day simple moving average of $18.21. The company has a market cap of $4.98 billion, a P/E ratio of 75.21 and a beta of 0.53.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.